Latest Regulatory Environment News

EQT Holdings Limited reported record funds under management and a solid financial performance for FY25, successfully completing its three-year strategic integration program. The company’s margin recovery and dividend growth signal a confident outlook amid ongoing regulatory challenges.

Equity Trustees reports record funds under management of $254 billion and a 60% jump in statutory net profit, completing a transformative three-year strategic agenda.

EQT Holdings Limited reported a robust FY25 with a 60% jump in net profit and record funds under management, while completing a major acquisition integration and raising dividends.

Xamble Group Limited (ASX, XGL) has announced a pro-rata renounceable entitlement offer to raise up to A$1.36 million, including free attaching options exercisable until 2028. The offer is partially underwritten by Eli Capital Pty Limited and aims to accelerate platform growth and technology development.

Smart Parking Limited delivered record FY25 results, driven by strong organic growth and the strategic acquisition of Peak Parking in the USA, setting the stage for ambitious global expansion.

The Papua New Guinea Mining Advisory Committee has recommended extending St Barbara's Simberi Mining Lease to 2038, aligning with plans to boost gold production beyond 200,000 ounces annually.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.

Bank of Queensland Limited announces a fully franked quarterly distribution of AUD 1.337 per Capital Note 3 security, payable in November 2025. The payment reflects a total annualised rate of 5.19%, based on the 3-month BBSW plus margin, adjusted for franking credits.

Aurizon Holdings reported a 3% decline in underlying EBITDA and a 14% drop in NPAT for FY2025, while unveiling a $150 million on-market buy-back and a $500 million subordinated notes issuance to strengthen its balance sheet.

Neurizon Therapeutics faces a delay in FDA review for its lead ALS therapy NUZ-001, with a new decision expected by early October amid agency-wide staffing challenges.

Cochlear Limited has announced a fully franked ordinary dividend of AUD 2.15 per share for the six months ending June 2025, payable in October with multi-currency options for shareholders.

BPH Energy has responded to an ASX price query following unusual trading activity, confirming no undisclosed information exists and pointing to ongoing legal matters involving its investee Advent Energy as context.